Thoracic Surgery

Treatment for Early and Locally Advanced Lung Cancer

At a Glance

Treatment for early and locally advanced lung cancer depends on the cancer type, stage, biomarker results, tumor location, and overall health. Options may include surgery, radiation, chemotherapy, immunotherapy, targeted therapy, and individualized brain monitoring for small cell lung cancer.

When lung cancer is found before it has spread extensively, the goal of treatment is typically to eliminate the cancer and prevent it from returning. Depending on the type and stage of your cancer, this may involve surgery, radiation, chemotherapy, immunotherapy, targeted therapy, or a combination of these modalities ^[1]^[2]^[3].

Early-Stage Non-Small Cell Lung Cancer (NSCLC)

For Stage I and II NSCLC, the primary focus is removing or destroying the tumor.

Surgery: Lobectomy (removing one of the five lobes of the lungs) along with lymph node assessment is a standard approach for fit patients ^[1]^[4]. For selected peripheral tumors smaller than 2 cm, an anatomic segmentectomy (a lung-sparing surgery) is now an accepted standard option that can provide comparable outcomes ^[5]^[6]. The choice depends on tumor size, location, lung function, and surgical fitness.
SBRT/SABR: If surgery is unsafe due to other health conditions, Stereotactic Body Radiation Therapy (SBRT) is a highly effective alternative ^[7]. It uses precisely aimed, high-dose radiation to destroy the tumor in a few sessions ^[8]^[9].

Locally Advanced NSCLC (Stages II-III)

When the cancer is larger or involves nearby lymph nodes, treatment often involves systemic therapy combined with local treatment.

Before Surgery (Neoadjuvant): For eligible patients with resectable Stage II or IIIA disease who do not have certain actionable mutations (like EGFR or ALK), a combination of chemotherapy and immunotherapy before surgery has become a standard option ^[10]^[11]. This aims to shrink the tumor and clear microscopic disease ^[10]^[12].
After Surgery (Adjuvant): Depending on your biomarker results, you may receive adjuvant therapy. For example, patients with EGFR-mutated or ALK-positive cancer may receive targeted therapy (like osimertinib or alectinib) after surgery to reduce recurrence risk ^[13]^[14].
Unresectable Stage III: If the cancer cannot be safely removed, the preferred treatment is concurrent chemoradiation (chemotherapy and radiation given simultaneously) for those who can tolerate it ^[2]^[15]. For eligible patients without disease progression following chemoradiation, up to one year of durvalumab (an immunotherapy) is standard to help keep the cancer at bay ^[16]^[17]. Patients with actionable driver mutations may have different post-chemoradiation options.

Limited-Stage Small Cell Lung Cancer (SCLC)

Limited-stage SCLC requires a fast and coordinated approach.

Concurrent Chemoradiation: The standard is chemotherapy (platinum-etoposide) given at the same time as thoracic radiation ^[3]. Doctors often prefer starting radiation early, during the first or second cycle ^[3]. The radiation may be given once daily or twice daily; the twice-daily schedule is often considered the benchmark for effectiveness if feasible ^[18].
Consolidation Immunotherapy: For eligible patients whose cancer has not progressed after chemoradiation, a new standard based on the ADRIATIC trial is to receive durvalumab for up to two years to help delay recurrence ^[19]^[20].
Managing Brain Metastasis Risk: Because SCLC often spreads to the brain, your team will discuss brain-directed strategies. Prophylactic Cranial Irradiation (PCI)—low-dose radiation to the whole brain—reduces but does not eliminate the risk of brain metastases ^[21]. However, because of potential neurocognitive side effects (impact on memory and thinking), PCI is a highly individualized choice. Many patients and doctors opt for active surveillance with frequent brain MRI scans instead of, or alongside, PCI ^[22]^[23].

Note: All treatments carry side effects. Surgery involves recovery time and risk of infection; radiation can cause esophagitis or pneumonitis; chemotherapy may lower blood counts; and immunotherapy carries risks of immune-related organ inflammation. Always discuss the specific side effect profile with your team.

Common questions in this guide

What are the main treatment options for stage I or II NSCLC?

For fit patients, surgery, often a lobectomy with lymph-node assessment, is commonly used to remove the tumor. For selected peripheral tumors smaller than 2 cm, an anatomic segmentectomy may preserve more lung tissue, while SBRT is an effective alternative when surgery is unsafe.

When might NSCLC treatment be given before or after surgery?

Eligible patients with resectable stage II or IIIA NSCLC may receive chemotherapy plus immunotherapy before surgery, particularly when certain EGFR or ALK alterations are absent. After surgery, biomarker results may support targeted therapy such as osimertinib or alectinib to reduce the risk of recurrence.

How is unresectable stage III NSCLC usually treated?

For patients who can tolerate it, chemotherapy and radiation are typically given at the same time. If the cancer has not progressed, durvalumab for up to one year is a standard consolidation option, although actionable driver mutations may change the treatment plan.

What treatment is used for limited-stage small cell lung cancer?

Treatment usually combines platinum-etoposide chemotherapy with thoracic radiation, often beginning during the first or second chemotherapy cycle. If the cancer has not progressed after chemoradiation, eligible patients may receive durvalumab for up to two years.

Should I have preventive brain radiation for small cell lung cancer?

Small cell lung cancer can spread to the brain, and prophylactic cranial irradiation can lower but not eliminate that risk. Because it may affect memory and thinking, the decision is individualized, and regular brain MRI surveillance may be used instead of or alongside this radiation.

What side effects can early or locally advanced lung cancer treatment cause?

Surgery can involve recovery time and infection risk, radiation can cause esophagitis or pneumonitis, and chemotherapy can lower blood counts. Immunotherapy can cause inflammation in organs when the immune system becomes overactive, so new or worsening symptoms should be discussed promptly with the treatment team.

Curated prompts to bring to your next appointment.

1.Based on my tumor size and location, am I a candidate for a lobectomy or an anatomic segmentectomy?
2.If my cancer is Stage II or IIIA, am I a candidate for chemoimmunotherapy before surgery, or targeted therapy after surgery?
3.For my Stage III NSCLC, will the chemotherapy and radiation be delivered concurrently, and will we use durvalumab afterward?
4.For my limited-stage SCLC, can we use the twice-daily radiation schedule, and am I eligible for durvalumab consolidation?
5.What are the pros and cons of Prophylactic Cranial Irradiation (PCI) versus regular brain MRI surveillance in my specific case?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Key takeaways

For stage I and II NSCLC, lobectomy or selected segmentectomy can remove the tumor, while SBRT is an effective alternative when surgery is unsafe.
Eligible patients with resectable stage II or IIIA NSCLC may receive chemotherapy and immunotherapy before surgery, and biomarker-directed therapy may follow surgery.
Unresectable stage III NSCLC is commonly treated with concurrent chemoradiation followed by durvalumab when there is no progression and the patient is eligible.
Limited-stage SCLC is typically treated with concurrent platinum-etoposide chemotherapy and thoracic radiation, followed by durvalumab for eligible patients without progression.
Prophylactic cranial irradiation can reduce but not eliminate brain metastasis risk in SCLC, and its cognitive risks should be weighed against regular brain MRI surveillance.

References (23)

1
Stage I non-small cell lung cancer: Treatment modalities, Dutch daily practice and future perspectives.
Hopstaken JS, de Ruiter JC, Damhuis RAM, et al.
Cancer treatment and research communications 2021; (28()):100404 doi:10.1016/j.ctarc.2021.100404.
PMID: 34058517
2
ASTRO Radiation Therapy Summary of the ASCO Guideline on Management of Stage III Non-Small Cell Lung Cancer.
Simone CB, Bradley J, Chen AB, et al.
Practical radiation oncology 2023; (13(3)):195-202 doi:10.1016/j.prro.2023.01.005.
PMID: 37080641
3
Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline.
Rudin CM, Ismaila N, Hann CL, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015; (33(34)):4106-11 doi:10.1200/JCO.2015.63.7918.
PMID: 26351333
4
What we know about surgical therapy in early-stage non-small-cell lung cancer: a guide for the medical oncologist.
Ghanem S, El Bitar S, Hossri S, et al.
Cancer management and research 2017; (9()):267-278 doi:10.2147/CMAR.S139253.
PMID: 28740431
5
Sublobar Resection vs Lobectomy for Stage IA Non-Small Cell Lung Carcinoma-Takeaways From Modern Randomized Trials.
Kneuertz PJ, Ferrari-Light D, Altorki NK
The Annals of thoracic surgery 2024; (117(5)):897-903 doi:10.1016/j.athoracsur.2023.12.008.
PMID: 38184163
6
Sublobar resection or lobectomy for stage Ia non-small cell lung cancer: a systematic review and meta-analysis.
Dixon LK, Barber E, Cook A, et al.
BMJ open respiratory research 2025; (12(1)) doi:10.1136/bmjresp-2025-003234.
PMID: 41173503
7
Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline.
Schneider BJ, Daly ME, Kennedy EB, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018; (36(7)):710-719 doi:10.1200/JCO.2017.74.9671.
PMID: 29106810
8
Stereotactic body radiation therapy for non-small cell lung cancer: A review.
Prezzano KM, Ma SJ, Hermann GM, et al.
World journal of clinical oncology 2019; (10(1)):14-27 doi:10.5306/wjco.v10.i1.14.
PMID: 30627522
9
Long-term quality of life in early-stage non-small cell lung cancer patients treated with robotic stereotactic ablative radiation therapy.
Mathieu D, Campeau MP, Bahig H, et al.
Practical radiation oncology 2015; (5(4)):e365-73.
PMID: 25680997
10
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
Forde PM, Spicer J, Lu S, et al.
The New England journal of medicine 2022; (386(21)):1973-1985 doi:10.1056/NEJMoa2202170.
PMID: 35403841
11
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial.
Spicer JD, Garassino MC, Wakelee H, et al.
Lancet (London, England) 2024; (404(10459)):1240-1252 doi:10.1016/S0140-6736(24)01756-2.
PMID: 39288781
12
Perioperative Nivolumab in Resectable Lung Cancer.
Cascone T, Awad MM, Spicer JD, et al.
The New England journal of medicine 2024; (390(19)):1756-1769 doi:10.1056/NEJMoa2311926.
PMID: 38749033
13
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation.
Occhipinti M, Imbimbo M, Ferrara R, et al.
The Cochrane database of systematic reviews 2025; (5()):CD015140 doi:10.1002/14651858.CD015140.pub2.
PMID: 40421698
14
Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.
Wu YL, Dziadziuszko R, Ahn JS, et al.
The New England journal of medicine 2024; (390(14)):1265-1276 doi:10.1056/NEJMoa2310532.
PMID: 38598794
15
Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R.
Filippi AR, Bar J, Chouaid C, et al.
ESMO open 2024; (9(6)):103464 doi:10.1016/j.esmoop.2024.103464.
PMID: 38833971
16
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer.
Herbst RS, Majem M, Barlesi F, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(29)):3383-3393 doi:10.1200/JCO.22.00227.
PMID: 35452273
17
Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: TORG1937 (DATE Study).
Nakamichi S, Kubota K, Misumi T, et al.
Clinical cancer research : an official journal of the American Association for Cancer Research 2024; (30(6)):1104-1110 doi:10.1158/1078-0432.CCR-23-2568.
PMID: 38165684
18
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
Faivre-Finn C, Snee M, Ashcroft L, et al.
The Lancet. Oncology 2017; (18(8)):1116-1125 doi:10.1016/S1470-2045(17)30318-2.
PMID: 28642008
19
Durvalumab: A Review in Limited-Stage Small Cell Lung Cancer.
France NL, Syed YY
Targeted oncology 2026; (21(2)):299-307 doi:10.1007/s11523-026-01207-2.
PMID: 41820709
20
ADRIATIC: When face value is enough.
Addeo A, Liu SV
Med (New York, N.Y.) 2024; (5(11)):1348-1350 doi:10.1016/j.medj.2024.10.004.
PMID: 39520980
21
Radiation Therapy for Small Cell Lung Cancer: An ASTRO Clinical Practice Guideline.
Simone CB, Bogart JA, Cabrera AR, et al.
Practical radiation oncology 2020; (10(3)):158-173 doi:10.1016/j.prro.2020.02.009.
PMID: 32222430
22
Use of radiation therapy among patients with Extensive-stage Small-cell lung cancer receiving Immunotherapy: Canadian consensus recommendations.
Sun A, Abdulkarim B, Blais N, et al.
Lung cancer (Amsterdam, Netherlands) 2023; (179()):107166 doi:10.1016/j.lungcan.2023.03.002.
PMID: 36944282
23
Radiation and Systemic Therapy for Limited-Stage Small-Cell Lung Cancer.
Bogart JA, Waqar SN, Mix MD
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(6)):661-670 doi:10.1200/JCO.21.01639.
PMID: 34985935

This page is for informational purposes only and does not constitute medical advice. Your oncology team should tailor treatment decisions to your lung cancer type, stage, biomarker results, and overall health.

Get notified when new evidence is published on lung cancer.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents